93 
MR. HUTT: Bob, are you going to provide very specific comments on 
particular provisions, because you have talked very generally. 
DR. BOCK: I am going to hand in the citations of the points in the 
Guidelines that I referred to. 
DR. FREDRICKSON: Professor Rosenblith. 
PROFESSOR ROSENBLITH: This is not a comment. I am sort of piggyback- 
ing a remark that I should inhibit for tomorrow, but tomorrow may never 
never come. 
DR. FREDRICKSON: This is the council trying to overcome that kind 
of pessimism. 
(Laughter . ) 
PROFESSOR ROSENBLITH: The thing that occurs to me that would really 
be quite helpful in this whole process, and I heard much anguish expressed 
this morning: Does the NIH have at the present time a mechanism whereby 
one could, perhaps every month or every two months, try to report to the 
public in a semi-popular fashion what is going on in this field, which is 
so much at the present time cast in a pioneering role, and not rely on the 
fact that when you come down to the crunch you have to communicate? It 
seems to me that there is evolving a climate out of the scientific litera- 
ture that one ought to try to communicate to the concerned public in a way 
that I don't think the shotgun experiments of publication at the present 
time do. 
DR. FREDRICKSON: Well, the answer to your question, Professor Rosenblith, 
is no, we do not. I suppose that we have been somewhat inhibited in the 
sense that being cast, though perhaps temporarily, in this quas i-regul atory 
role, we have not wanted to appear to be in conflict of interest. 
PROFESSOR ROSENBLITH: Well, maybe you will find somebody else who 
has just the interest, without conflict. 
DR. FREDRICKSON: We would like to find ourselves in that very position. 
Dr. Bock, I just wanted to add on to your comment. You said that maybe 
one percent of the time a lab might be actually engaged in the presence of, 
or operating upon, recombinant molecules. I would like to note that in the 
indices of the support that NIH gives to recombinant DNA research, we per- 
fectly well realize this, but we attribute every nickel of that grant to re- 
combinant DNA research. Thus, the amount of Federal expenditure attributed 
to recombinant DNA activities is vastly overstated by those same figures. 
At the present time, however, we simply do not have available an honest 
way of determining the fraction of the grant which is going toward these 
act ivities . 
[ 297 ] 
